News archive
Showing 678 results
September 2018
-
Media ReleaseNovartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project- Generation S offers the sickle cell community a powerful new way to share personal experiences and rewrite the story of an often-misunderstood disease- Singer-songwriter and actress Jordin Sparks…
-
Media ReleaseNovartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project
-
Media ReleaseNovartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis- The PARADIGMS study was the basis for the US Food and Drug Administration (FDA) approval of Gilenya (fingolimod) in May 2018 for pediatric patients (aged 10 to 17) with relapsing multiple sclerosis…
-
Media ReleaseNovartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
July 2018
-
Media ReleaseNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women- Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Media ReleaseNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
-
StatementNovartis Pharmaceuticals Corporation (Novartis) Statement on Recall Outside the United States of Sandoz Generic Valsartan and Sandoz Valsartan and Hydrochlorothiazide Film-Coated Tablets
-
Media ReleaseNovartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices…
-
Media ReleaseNovartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
-
Media ReleaseSandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance- Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements- Certain lots…
-
Media ReleaseSandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance